• François Rinaldi, Simon de Denus, Angela Nguyen, Stanley Nattel, and Jean-François Bussières.
• Département de pharmacie et Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal, Québec, Canada.
• Can J Cardiol. 2017 Feb 1; 33 (2): 283-286.

AbstractDrug shortages have been reported for > 35 years. Attention to this problem increased recently after the Sandoz crisis, in which a warning letter by the Food and Drug Administration caused supply changes that suspended the availability of numerous medications. The frequency of drug shortages has increased recently. In 2011-2012 alone, Canadian supply shortages occurred for > 1000 drugs (including 150 for cardiovascular diseases). These shortages lasted for an average of 4-5 months, increasing the workload for health care providers, producing impaired health, stress, and anxiety for patients, and increasing the risk of errors. The critical importance of drug shortages is increasingly recognized by members of the public, and health care providers must sometimes make major efforts to minimize their adverse consequences. Although data are limited, such efforts come at a price that patients and the health care system should not have to bear; they divert pharmacists and physicians from their already busy clinical duties and often require complex and risky adjustments in medical regimens. If drug shortages are here to stay, clinicians, drug manufacturers, and relevant organizations should work together to increase accountability for drug availability and adaptation to shortages, and to create more effective tools with which to anticipate and respond to critical supply fluctuations.Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

8 keywords...

hide…